GO-2301
Wet age-related macular degeneration (AMD) and diabetic retinopathy
PreclinicalActive
Key Facts
Indication
Wet age-related macular degeneration (AMD) and diabetic retinopathy
Phase
Preclinical
Status
Active
Company
About General Oncology
General Oncology is an emerging biotech focused on metastatic cancers with high unmet need, originating from a compelling n-of-1 case of a BRCA2+ pancreatic cancer patient treated successfully with melphalan. The company's lead asset, GO-4305C, reported a median progression-free survival of 14.2 months in a 12-patient Phase 1 trial (SHARON) in stage IV BRCA-associated pancreatic ductal adenocarcinoma, with two patients remaining disease-free for over 2.5 years. With a preclinical ophthalmology program in development and a lean team, the company is advancing its novel, multi-modal therapeutic approach while seeking to validate its platform in larger studies.
View full company profile